Thijs Veerman
CEO
Catherinn BV
Leiden, Netherlands
7 profile visits
Catherinn develops immunotherapy and diagnostic solutions for Small Cell Lung Cancer patients with our proprietary NCAM180 biomarker
My organisation
Catherinn BV (Cancer Therapeutics and Innovation) is a virtual research and development company devoted to the improvement of diagnostic and treatment options for Small Cell Lung Cancer (SCLC) patients. Catherinn was started by a group of highly motivated experts and entrepreneurs in the life science and vaccine industry. We are committed to improving the lives of SCLC cancer patients, both by prevention through early screening and by cure through immunotherapy.
About me
former CEO Netherlands Vaccine Institute
currently: CEO Catherinn and advisor to INFECTA (www.infecta.org)